A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Overall survival (OS)

Time frame: Up to 5 years after the last participant is randomized

Overall response rate (ORR)

Time frame: Up to 5 years after the last participant is randomized

Minimal residual disease (MRD)-negative status

Time frame: Up to 5 years after the last participant is randomized

Complete response rate (CRR)

Time frame: Up to 5 years after the last participant is randomized

Time to response (TTR)

Time frame: Up to 5 years after the last participant is randomized

Duration of response (DOR)

Time frame: Up to 5 years after the last participant is randomized

Maximum observed concentration (Cmax) of transgene level

Time frame: Up to 5 years after the last participant is randomized

Time of maximum observed plasma concentration (Tmax) of transgene level

Time frame: Up to 5 years after the last participant is randomized

Area under the concentration-time curve (AUC) of transgene level

Time frame: Up to 5 years after the last participant is randomized

Changes from baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 items (QLQ-C30) primary domains

EORTC QLQ-C30 primary domains: fatigue, pain, physical functioning, role functioning, cognitive functioning, and global health status/quality of life (QoL).

Time frame: Up to 5 years after the last participant is randomized

Changes from baseline in EORTC Quality of Life Multiple Myeloma Module- 20 items (QLQ-MY20) primary domains

EORTC QLQ-MY20 primary domains: disease symptoms and side effects of treatment

Time frame: Up to 5 years after the last participant is randomized

Time to meaningful improvement in EORTC QLQ-C30 global health status/QoL.

Time frame: Up to 5 years after the last participant is randomized